ClinicalTrials.gg
Active, not recruitingNCT05743881Updated Jun 26, 2026

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

A Phase 1 interventional study of mRNA-1345 and mRNA-1365 in Respiratory Syncytial Virus and Human Metapneumovirus, sponsored by ModernaTX, Inc.. Active, not recruiting at 17 sites in 3 countries. Open to participants aged 5 Months to 24 Months. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
5 Months to 24 Months
Sex
All
01

Study summary

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.

02

Conditions studied

  • Respiratory Syncytial Virus
  • Human Metapneumovirus

Keywords

  • mRNA-1345
  • mRNA-1365
  • RSV vaccine
  • hMPV vaccine
  • RSV/hMPV vaccine
03

In context

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • The participant is 8 months to \<24 months (Part A), 5 months to \<8 months (Part B), or 8 months to \<12 months (Part C) of age at the time of randomization (Day 1/Baseline visit), who is in good general health, in the opinion of the Investigator, based on review of medical history and screening physical examination.
  • In the Investigator's opinion, the parent(s)/ legally authorized representative (LAR)(s) understand and are willing and physically able to comply with protocol-mandated follow up, including all procedures, and provide written .
  • The participant is growing normally for age in the opinion of the site clinician in the months prior to enrollment.
  • The participant was born at full-term (≥37 weeks gestation) with a minimum birth weight of 2.5 kilograms (kg).
  • For Part C Cohort 7: participant must have received nirsevimab ≥6 months prior to Day 1 Visit.
  • For Part C Cohort 8: participant was eligible at any time since birth, according to national guidelines, to receive nirsevimab prior to Day 1 Visit but did not do so.

Exclusion Criteria:

  • Has a known history of symptomatic RSV (Part A: within 3 months; Part B and Part C: since birth) or hMPV infection (Part A: within 3 months; Part B: since birth) prior to administration of the first dose of product (IP) or has a known close contact with anyone with laboratory-confirmed RSV (Parts A, B, and C) or hMPV infection (Parts A or B) within 14 days prior to administration of the first dose of IP.
  • Is acutely ill or febrile 24 hours prior to or at the screening visit. Fever is defined as a body temperature ≥38.0°Celsius/≥100.4°Fahrenheit. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows.
  • Has previously been administered an investigational or approved vaccine for prevention of RSV (Parts A, B, and C) or hMPV (Parts A and B) infection or if the participant's mother received an investigational or approved vaccine for the prevention of RSV (Parts A, B, and C) or hMPV (Parts A and B) infection during pregnancy.
  • Has received investigational or approved agents for prophylaxis against RSV or hMPV (for example, monoclonal antibodies) or is intending to receive these during the course of the study. For Part C (Cohort 7 only), use of nirsevimab ≥6 months before Day 1 Visit is allowed.
  • Has a known to a component of the vaccine or its . Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mRNA vaccine or any of its components (including polyethylene glycol or immediate allergic reaction of any severity to polysorbate).
  • Has a medical condition that, according to the Investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.

Note: Other protocol-defined inclusion/exclusion criteria apply.

Inclusion Criteria:

  • For Part B Extension: participants enrolled and dosed in Part B (Cohorts 3 to 6); either reached the end of study of the Main Study or were dosed and subsequently discontinued from the Main Study. This includes participants who were lost to follow-up, if they can be re-engaged.
  • For Part B Extension: participant's parent(s)/LAR(s) has provided written informed consent for participation in Part B of the Main Study and the Part B Extension.

Exclusion Criteria:

  • For Part B Extension, there are no specific exclusion criteria.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Part A: mRNA-1345, Dose 1 (Age Group: 8 to <24 months)

    Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.

    Biological: mRNA-1345

  • Experimental
    Part A: mRNA-1365, Dose 1 (Age Group: 8 to <24 months)

    Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.

    Biological: mRNA-1365

  • Placebo comparator
    Part A: Placebo (Age Group: 8 to <24 months)

    Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.

    Biological: Placebo · Drug: Nimenrix

  • Experimental
    Part B: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)

    Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.

    Biological: mRNA-1345

  • Experimental
    Part B: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)

    Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.

    Biological: mRNA-1365

  • Experimental
    Part B: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)

    Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.

    Biological: mRNA-1345

  • Experimental
    Part B: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)

    Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.

    Biological: mRNA-1365

  • Placebo comparator
    Part B: Placebo (Age Group: 5 to <8 months)

    Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113. In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.

    Biological: Placebo · Drug: Nimenrix

  • No intervention
    Part B Extension: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)

    Participants will have the option to re-enrol in the Part B extension period.

  • No intervention
    Part B Extension: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)

    Participants will have the option to re-enrol in the Part B extension period.

  • No intervention
    Part B Extension: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)

    Participants will have the option to re-enrol in the Part B extension period.

  • No intervention
    Part B Extension: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)

    Participants will have the option to re-enrol in the Part B extension period.

  • No intervention
    Part B Extension : Placebo (Age Group: 5 to <8 months)

    Participants will have the option to re-enrol in the Part B extension period.

  • Experimental
    Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months exposed to nirsevimab)

    Participants who have been previously exposed to nirsevimab will receive mRNA 1345 by IM injection on Days 1, 57, and 113.

    Biological: mRNA-1345

  • Experimental
    Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months not exposed to nirsevimab)

    Participants who have not been previously exposed to nirsevimab will receive mRNA 1345 by IM injection on Days 1, 57, and 113.

    Biological: mRNA-1345

Interventions

  • BiologicalmRNA-1345

    Sterile liquid for injection

  • BiologicalmRNA-1365

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) solution for injection

  • DrugNimenrix

    Solution for injection

06

What researchers measure

Primary outcomes

  1. Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 120 (7 days after each injection)

  2. Main Study: Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 141 (28 days after each injection)

  3. Main Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)

    Time frame: Day 1 through Day 730

  4. Main Study: Number of Participants with Adverse Event of Special Interests (AESIs), Serious Adverse Events (SAEs) and Adverse Events Leading to Discontinuation

    Time frame: Day 1 through Day 730

  5. Part B Extension: Number of Participants with MAAEs, AESIs and SAEs

    Time frame: Day 1 of the Extension to end of study (EoS) (up to 3 years)

  6. Part B Extension: Number of Participants with Lower Respiratory Tract Illness (LRTI), Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPV

    Time frame: Day 1 of the Extension to EoS (up to 3 years)

Secondary outcomes

  1. Main Study: Number of Participants with Respiratory tract Illness (RTI), LRTI, Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPV

    Time frame: Day 1 through Day 730

  2. Main Study (Parts A and B): Geometric Mean Titer (GMT) of Serum RSV and hMPV Neutralizing Antibodies

    Time frame: Baseline up to Month 12

  3. Main Study (Part C): GMT of Serum RSV Neutralizing Antibodies

    Time frame: Baseline up to Month 12

  4. Main Study (Parts A and B): Geometric Mean Concentration (GMC) of Serum RSV F- and hMPV F-Binding Antibodies

    Time frame: Baseline up to Month 12

  5. Main Study (Part C): GMC of Serum RSV F-Binding Antibodies

    Time frame: Baseline up to Month 12

  6. Main Study: Geometric Mean Fold-Rise (GMFR) of Postbaseline/baseline Neutralizing Antibody Titers and Binding Antibody

    Time frame: Month 12

  7. Main Study: Number of Participants with Vaccine-specific T-cell Responses Measured by Flow Cytometry

    Time frame: Baseline up to Month 12

  8. Part B Extension: Geometric Mean Titer (GMT) of Serum RSV and hMPV Neutralizing Antibodies

    Time frame: Day 1 of the Extension up to EoS (up to 3 years)

  9. Part B Extension: Geometric Mean Concentration (GMC) of Serum RSV F- and hMPV F-Binding Antibodies

    Time frame: Day 1 of the Extension up to EoS (up to 3 years)

  10. Part B Extension: Geometric Mean Fold-Rise (GMFR) of Postbaseline/baseline Neutralizing Antibody Titers and Binding Antibody

    Time frame: Day 1 of the Extension up to EoS (up to 3 years)

  11. Part B Extension: Number of Participants with Vaccine-specific T-cell Responses Measured by Flow Cytometry

    Time frame: Day 1 of the Extension up to EoS (up to 3 years)

07

Study locations

17 sites
08

References and documents

Publications

  • Amodio D, Angelidou A, Cotugno N, Sherman AC, Levy O, Palma P; IPVC 2023 Speakers' group. Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference. Vaccine. 2025 Jan 1;43(Pt 2):126477. doi: 10.1016/j.vaccine.2024.126477. Epub 2024 Nov 28. PubMed 39608233 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Aug 2029, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Feb 24, 2023
StartActual
Feb 15, 2023
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743881
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Feb 15, 2023
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Jun 26, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion